1. Cvitkovic, E. (1998). Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treatment Reviews, 24, 265–281.
2. Hanigan, M. H., & Devarajan, P. (2003). Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Therapy, 1, 47–61.
3. Mollman, J. E., Glover, D. J., Hogan, W. M., & Furman, R. E. (1988). Cisplatin neuropathy risk factors, prognosis and protection by WR-2721. Cancer, 61, 2192–2195.
4. Screnci, D., & McKeage, M. J. (1999). Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches. Journal of Inorganic Biochemistry, 77, 105–110.
5. Brady, H. R., Kone, B. C., Stromski, M. E., Zeidel, M. L., Giebisch, G., & Gullans, S. R. (1990). Mitochondrial injury: An early event in cisplatin toxicity to renal proximal tubules. American Journal of Physiology, 258, 1181–1187.